AURO-TELMISARTAN HCTZ TABLET

Country: Kanada

Bahasa: Inggeris

Sumber: Health Canada

Bahan aktif:

TELMISARTAN; HYDROCHLOROTHIAZIDE

Boleh didapati daripada:

AURO PHARMA INC

Kod ATC:

C09DA07

INN (Nama Antarabangsa):

TELMISARTAN AND DIURETICS

Dos:

80MG; 25MG

Borang farmaseutikal:

TABLET

Komposisi:

TELMISARTAN 80MG; HYDROCHLOROTHIAZIDE 25MG

Laluan pentadbiran:

ORAL

Unit dalam pakej:

30/100/500/1000

Jenis preskripsi:

Prescription

Kawasan terapeutik:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Ringkasan produk:

Active ingredient group (AIG) number: 0244783002; AHFS:

Status kebenaran:

APPROVED

Tarikh kebenaran:

2016-07-18

Ciri produk

_Auro-Telmisartan HCTZ Product Monograph _Page 1 of 64
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AURO-TELMISARTAN HCTZ
Telmisartan and Hydrochlorothiazide Tablets, USP
Tablet, 80 mg/12.5 mg and 80 mg/25 mg, Oral
Angiotensin II AT
1
Receptor Blocker/ Diuretic
Auro Pharma Inc.
3700 Steeles Avenue West, Suite # 402
Woodbridge, Ontario, L4L 8K8,
Canada
Date of initial Authorization:
July 18, 2016
Date of Revision:
January 26, 2023
Submission Control No: 267665
_Auro-Telmisartan HCTZ Product Monograph _Page 2 of 64
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
01 / 2023
7 WARNINGS AND PRECAUTIONS
01 / 2023
4 DOSAGE AND ADMINISTRATION
01 / 2023
TABLE OF CONTENTS
_Sections or subsections that are not applicable at the time of
authorization are not listed. _
RECENT MAJOR LABEL CHANGES
..............................................................................................
2
TABLE OF CONTENTS
................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1 INDICATIONS
........................................................................................................................
4
1.1 Pediatrics
............................................................................................................................................
4
1.2 Geriatrics
............................................................................................................................................
4
2 CONTRAINDICATIONS
...........................................................................................................
4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
.......................................................................
5
4 DOSAGE AND ADMINISTRATION
...........................................................................................
5
4.1 Dosing Considerations
...................................................